We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

23 hedge funds and large institutions have $1.68M invested in Cardiff Oncology in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

50% more capital invested

Capital invested by funds: $1.11M → $1.68M (+$562K)

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

10% more funds holding

Funds holding: 21 → 23 (+2)

4.93% more ownership

Funds ownership: 7.39% → 12.33% (+4.9%)

Holders
23
Holders Change
+2
Holders Change %
+9.52%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$697K
2
Renaissance Technologies
Renaissance Technologies
New York
+$285K
3
Morgan Stanley
Morgan Stanley
New York
+$86.5K
4
EP
Elkhorn Partners
Nebraska
+$64.1K
5
TSS
Two Sigma Securities
New York
+$32.8K

Top Sellers

Rank Fund Capital Flow
1
FIA
FNY Investment Advisers
New York
-$7K
2
ARTA
A.R.T. Advisors
New York
-$6.68K
3
PCM
Princeton Capital Management
New Jersey
-$317

CRDF Hedge Fund Activity: Q2 2019 in Review

23 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2019, worth a combined $1.68M — up 50% from $1.11M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CRDF positions and 4 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $697K. The largest seller was FNY Investment Advisers, exiting entirely with an estimated $7K sold.

  • 23 institutional investors held Cardiff Oncology (CRDF) as of Q2 2019, up from 21 in Q1 2019.
  • Funds reported $1.68M of Cardiff Oncology stock for Q2 2019, up 50% quarter-over-quarter.
  • 6 funds opened new Cardiff Oncology positions in Q2 2019 and 4 closed out, a net change of +2 holders.
  • The largest Cardiff Oncology buyer in Q2 2019 was Vanguard Group, an estimated $697K added.
  • The largest Cardiff Oncology seller in Q2 2019 was FNY Investment Advisers, an estimated $7K sold.

Based on aggregated 13F filings for Q2 2019.